Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey.

Conclusions: The decline of complaints with different treatment schemes in different patients suggests that treatment should be designed individually and that personal biomarkers playing a role in the effectiveness of the drug are important. Patients with the high IgE and eosinophil percentages and positive autologous serum test had a better treatment response to omalizumab treatment. Meanwhile, remission was found to be more frequent in atopic dermatitis patients with omalizumab treatment compared to the patients with urticaria. It may be more appropriate to choose patients based on certain criteria to ensure cost-effectiveness in omalizumab treatment. PMID: 31998003 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research